Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)

Aim. The CORD Study compared effectiveness and tolerability of losartan and ramipril in patients with arterial hypertension (AH).Material and methods. The study included two groups, A and B. In Group A (n=4016; mean age 62,6+11,6 years; 53,1% women), the patients with blood pressure (BP) <160...

Full description

Bibliographic Details
Main Authors: J. Spinar, J. Vftovec, M. Soucek, L. Dusek, T. Pavlik
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2009-08-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1816
_version_ 1797882670097629184
author J. Spinar
J. Vftovec
M. Soucek
L. Dusek
T. Pavlik
author_facet J. Spinar
J. Vftovec
M. Soucek
L. Dusek
T. Pavlik
author_sort J. Spinar
collection DOAJ
description Aim. The CORD Study compared effectiveness and tolerability of losartan and ramipril in patients with arterial hypertension (AH).Material and methods. The study included two groups, A and B. In Group A (n=4016; mean age 62,6+11,6 years; 53,1% women), the patients with blood pressure (BP) <160/100 mm Hg and ACE inhibitor therapy lasting for >3 months were switched from ACE inhibitors to losartan. At baseline and 1, 3, 6, and 12 months later, BP, heart rate, and biochemical parameters were measured; general blood assay and electrocardiography (ECG) were also performed. In group B (n=3813; mean age 60,5+12,2 years; 50,5% women), the patients with BP >140/90 mm Hg and no previous ACE inhibitor or angiotensin receptor blocker (ARB) therapy were randomly administered either losartan (50 mg/d; n=1887) or ramipril (5 mg/d; n=1926).Results. Group A demonstrated a decrease in BP — from 147,4+14,8/87,7+9,3 to 139,7+11,8/83,0+9,3 mm Hg (p<0,001) after one month of the treatment, and to 133,7+11,3/79,1+7,06 mm Hg (p<0,001) after one year. Adverse effect prevalence did not increase. After one year, Group B demonstrated a reduction in BP levels — in losartan subgroup, from 156,5+13,1/93,4+8,8 to 134,55+11,3/80,16+6,6 mm Hg (p<0,001), and in ramipril subgroup — from 155,9+13,1/93,0+8,9 to 134,1+11,2/81,5+6,8 mm Hg (p<0,001). No severe adverse effects were registered, but in ramipril subgroup, cough was 8 times more prevalent.Conclusion. ACE inhibitor substitution with losartan was safe and effective. Losartan and ramipril demonstrated equal antihypertensive effectiveness and a tendency to improve metabolic parameters. Losartan therapy was better tolerated than ramipril.
first_indexed 2024-04-10T03:38:21Z
format Article
id doaj.art-6d479bd1b1b64820b0fb6e5a2219eecd
institution Directory Open Access Journal
issn 1728-8800
2619-0125
language Russian
last_indexed 2024-04-10T03:38:21Z
publishDate 2009-08-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj.art-6d479bd1b1b64820b0fb6e5a2219eecd2023-03-13T07:23:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-08-018463701531Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)J. Spinar0J. Vftovec1M. Soucek2L. Dusek3T. Pavlik4Университет МасарикаУниверситет МасарикаУниверситет МасарикаУниверситет МасарикаУниверситет МасарикаAim. The CORD Study compared effectiveness and tolerability of losartan and ramipril in patients with arterial hypertension (AH).Material and methods. The study included two groups, A and B. In Group A (n=4016; mean age 62,6+11,6 years; 53,1% women), the patients with blood pressure (BP) <160/100 mm Hg and ACE inhibitor therapy lasting for >3 months were switched from ACE inhibitors to losartan. At baseline and 1, 3, 6, and 12 months later, BP, heart rate, and biochemical parameters were measured; general blood assay and electrocardiography (ECG) were also performed. In group B (n=3813; mean age 60,5+12,2 years; 50,5% women), the patients with BP >140/90 mm Hg and no previous ACE inhibitor or angiotensin receptor blocker (ARB) therapy were randomly administered either losartan (50 mg/d; n=1887) or ramipril (5 mg/d; n=1926).Results. Group A demonstrated a decrease in BP — from 147,4+14,8/87,7+9,3 to 139,7+11,8/83,0+9,3 mm Hg (p<0,001) after one month of the treatment, and to 133,7+11,3/79,1+7,06 mm Hg (p<0,001) after one year. Adverse effect prevalence did not increase. After one year, Group B demonstrated a reduction in BP levels — in losartan subgroup, from 156,5+13,1/93,4+8,8 to 134,55+11,3/80,16+6,6 mm Hg (p<0,001), and in ramipril subgroup — from 155,9+13,1/93,0+8,9 to 134,1+11,2/81,5+6,8 mm Hg (p<0,001). No severe adverse effects were registered, but in ramipril subgroup, cough was 8 times more prevalent.Conclusion. ACE inhibitor substitution with losartan was safe and effective. Losartan and ramipril demonstrated equal antihypertensive effectiveness and a tendency to improve metabolic parameters. Losartan therapy was better tolerated than ramipril.https://cardiovascular.elpub.ru/jour/article/view/1816артериальная гипертензияизолированная систолическая гипертензиярамиприллозартанметаболические параметрыкашель
spellingShingle J. Spinar
J. Vftovec
M. Soucek
L. Dusek
T. Pavlik
Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
Кардиоваскулярная терапия и профилактика
артериальная гипертензия
изолированная систолическая гипертензия
рамиприл
лозартан
метаболические параметры
кашель
title Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
title_full Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
title_fullStr Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
title_full_unstemmed Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
title_short Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
title_sort comparing recommended doses of angiotensin receptor blockers and ace inhibitors cord study
topic артериальная гипертензия
изолированная систолическая гипертензия
рамиприл
лозартан
метаболические параметры
кашель
url https://cardiovascular.elpub.ru/jour/article/view/1816
work_keys_str_mv AT jspinar comparingrecommendeddosesofangiotensinreceptorblockersandaceinhibitorscordstudy
AT jvftovec comparingrecommendeddosesofangiotensinreceptorblockersandaceinhibitorscordstudy
AT msoucek comparingrecommendeddosesofangiotensinreceptorblockersandaceinhibitorscordstudy
AT ldusek comparingrecommendeddosesofangiotensinreceptorblockersandaceinhibitorscordstudy
AT tpavlik comparingrecommendeddosesofangiotensinreceptorblockersandaceinhibitorscordstudy